| 1 minute

CRO Secures Extended Agreement with UK-Based Biotech Firm

Concept Life Sciences’ recent acquisition of Aquila BioMedical has quickly produced a return—an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.

Aquila will run a few in vitro, in vivo and ex vivo analyses to help Macrophage decide on the best candidate to enter the clinic.

U.K.-based Macrophage targets cancer with its proprietary Esterase Sensitive Motif (ESM) technology, which delivers small-molecule drugs to influence only tumor-associated macrophages so that their suppression on the body’s natural immune system could be lifted.


To read the full article, click here.

Back to News

Do you have news for the Scottish Life Sciences Community?

Submit Your Own News